scispace - formally typeset
Journal ArticleDOI

Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.

Reads0
Chats0
TLDR
In type 2 diabetes, treatment with SGLT2i or GLP-1 compared with DPP-4 or sulfonylureas was associated with a lower risk of adverse kidney outcomes.
Abstract
OBJECTIVE To examine the comparative effectiveness of sodium–glucose cotransporter 2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP-1), dipeptidyl peptidase 4 inhibitors (DPP-4), and sulfonylureas on risk of kidney outcomes among people with type 2 diabetes. RESEARCH DESIGN AND METHODS U.S. veterans initiated on SGLT2is (n = 18,544), GLP-1 (n = 23,711), DPP-4 (n = 39,399), or sulfonylureas (n = 134,904) were followed for up to 3 years to evaluate the risk of the composite outcome of estimated glomerular filtration rate (eGFR) decline >50%, end-stage kidney disease (ESKD), or all-cause mortality. Risks were estimated using survival models adjusted for predefined covariates as well as covariates identified by a high-dimensional variable selection algorithm through application of generalized propensity scores. RESULTS Compared with those treated with sulfonylureas, treatment with SGLT2is, GLP-1, and DPP-4 was associated with a lower risk of the composite outcome (hazard ratio 0.68 [95% CI 0.63, 0.74], 0.72 [0.67, 0.77], and 0.90 [0.86, 0.95], respectively). While we did not observe a statistically significant difference in risk between the SGLT2i and GLP-1 arms (0.95 [0.87, 1.04]), both SGLT2is and GLP-1 had a lower risk of the composite outcome than DPP-4 (0.76 [0.70, 0.82] and 0.79 [0.74, 0.85], respectively). Analyses by eGFR category suggested that compared with the sulfonylurea arm, those in the SGLT2i and GLP-1 arms exhibited a lower risk of the composite outcome in all eGFR categories, including eGFR CONCLUSIONS In type 2 diabetes, treatment with SGLT2is or GLP-1 compared with DPP-4 or sulfonylureas was associated with a lower risk of adverse kidney outcomes.

read more

Citations
More filters
Journal ArticleDOI

High-dimensional characterization of post-acute sequelae of COVID-19.

TL;DR: In this paper, the authors used the national healthcare databases of the US Department of Veterans Affairs to systematically and comprehensively identify 6-month incident sequelae, including diagnoses, medication use and laboratory abnormalities, in patients with COVID-19 who survived for at least 30 days after diagnosis.
Journal ArticleDOI

Risks and burdens of incident diabetes in long COVID: a cohort study

TL;DR: In this paper , the authors examined the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection.
Journal ArticleDOI

Risks of mental health outcomes in people with covid-19: cohort study

Yan Xie, +2 more
- 16 Feb 2022 - 
TL;DR: People who survive the acute phase of covid-19 are at increased risk of an array of incident mental health disorders, including anxiety disorders, depression disorders, and other (non-opioid) substance use disorders.
Journal ArticleDOI

Risks and burdens of incident diabetes in long COVID: a cohort study

TL;DR: Increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era are reported.
Journal ArticleDOI

Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status.

TL;DR: The burden of post-acute Sequelae of SARS-CoV-2 infection (PASC) has been characterized; however, the burden of PASC remains unknown.
References
More filters
Journal Article

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 - 
TL;DR: In this article, the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Theo Vos, +778 more
- 16 Sep 2017 - 
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016.
Journal Article

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

TL;DR: The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI

Global, regional, and national incidence, prevalence, andyears lived with disability for 354 diseases and injuries for195 countries and territories, 1990–2017: a systematicanalysis for the Global Burden of Disease Study 2017

TL;DR: All-cause age-standardised YLD rates decreased by 3·9% from 1990 to 2017; however, the all-age YLD rate increased by 7·2% while the total sum of global YLDs increased from 562 million (421–723) to 853 million (642–1100).
Related Papers (5)